About this trial
This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
The patient (male) is aged 18 years or above.
The patient is able to understand the information presented to him concerning the nature, scope, and consequences of the trial as set out in the information provided to the patient AND has provided written informed consent to participate.
The patient has newly diagnosed, biopsy-proven, clinically localized prostate adenocarcinoma, and curative prostatectomy with extended pelvic lymph node dissection is his preferred course of treatment.
Overall ISUP grade group 4 or 5,
Disqualifiers
Patients for whom radical prostatectomy is not clinically appropriate or the patient is otherwise unlikely to undergo radical prostatectomy with extensive pelvic lymph node dissection.
The patient has received any therapy - be it radiation, surgical or drug therapy - for his prostate cancer.
The patient has any contraindication(s) for and/or known hypersensitivity to any constituent(s) of [18F]PSMA-1007.
The patient is not able to have PET-CT scans (for example, because of weight, claustrophobia, or inability to lie still for the duration of the scan).
Trial design
Single group
Treatments tested in this trial
[18F]PSMA-1007
DrugDiagnostic radiopharmaceutical for PET scan
Treatment groups
Trial outcomes
Primary outcomes
Sensitivity and specificity of [18F]PSMA-1007 PET/CT for the detection of pelvic nodal disease (N1) compared to histology as the standard of reference
Sponsors and contacts
Click on the lead sponsor to view all of their trials.